Enhanced effect of gemcitabine by emodin against pancreatic cancer in vivo via cytochrome C-regulated apoptosis

Oncology Reports

Volumn 25, Issue 5, 2011, Pages 1253-1261

  Chen, Hui ^a   Wei, Weitian ^a   Guo, Yafei ^a   Liu, An ^a   Tong, Hongfei ^a   Wang, Zhaohong ^a   Tan, Wei ^a   Liu, Jinxiang ^a   Lin, Shengzhang ^a  

^a WENZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Apoptosis; Bax; Bcl 2; Cytochrome C; Emodin; Gemcitabine

Indexed keywords

CASPASE 3; CYTOCHROME C; EMODIN; GEMCITABINE; KI 67 ANTIGEN; PROTEIN BAX; PROTEIN BCL 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CONTROLLED STUDY; CYTOPLASM; DOWN REGULATION; DRUG ANTAGONISM; ENZYME ACTIVATION; FEMALE; HUMAN; HUMAN CELL; MITOCHONDRION; MONOTHERAPY; MOUSE; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN SECRETION;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CASPASE 3; CELL LINE, TUMOR; CELL PROLIFERATION; CYTOCHROMES C; DEOXYCYTIDINE; DRUG SYNERGISM; EMODIN; FEMALE; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; PANCREATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79953065053     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2011.1174     Document Type: Article

References (35)

1. Jemal A, Thomas A, Murray T and Thun M: Cancer statistics, 2002. CA Cancer J Clin 52: 23-47, 2002.
2. Mangray S and King TC: Molecular pathobiology of pancreatic adenocarcinoma. Front Biosci 3: D1148-D1160, 1998.
3. Hilbig A and Oettle H: Adjuvant therapy of pancreatic cancer. Expert Rev Anticancer Ther 10: 485-491, 2010.
4. Oettle H, Post S, Neuhaus P, et al: Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative- intent resection of pancreatic cancer: a randomized controlled trial. JAMA 297: 267-277, 2007. (Pubitemid 46143304)
5. Tempero MA, Behrman S, Ben-Josef E, et al: Pancreatic adenocarcinoma: clinical practice guidelines in oncology. J Natl Compr Canc Netw 3: 598-626, 2005. (Pubitemid 44265410)
6. Oettle H and Riess H: Gemcitabine in combination with 5-fluorouracil with or without folinic acid in the treatment of pancreatic cancer. Cancer 95: 912-922, 2002. (Pubitemid 34839686)
7. Burris HA III, Moore MJ, Andersen J, et al: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15: 2403-2413, 1997. (Pubitemid 27251144)
8. Burris H and Storniolo AM: Assessing clinical benefit in the treatment of pancreas cancer: gemcitabine compared to 5-fluorouracil. Eur J Cancer 33 (Suppl. 1): S18-S22, 1997.
9. Bader Y, Hartmann J, Horvath Z, et al: Synergistic effects of deuterium oxide and gemcitabine in human pancreatic cancer cell lines. Cancer Lett 259: 231-239, 2008. (Pubitemid 350251645)
10. Nakagawa T, Shimizu M, Shirakami Y, Tatebe H, Yasuda I, Tsurumi H and Moriwaki H: Synergistic effects of acyclic retinoid and gemcitabine on growth inhibition in pancreatic cancer cells. Cancer Lett 273: 250-256, 2009.
11. Lee SH, Ryu JK, Lee KY, et al: Enhanced anti-tumor effect of combination therapy with gemcitabine and apigenin in pancreatic cancer. Cancer Lett 259: 39-49, 2008. (Pubitemid 350235089)
12. Wang SJ, Gao Y, Chen H, et al: Dihydroartemisinin inactivates NF-kappaB and potentiates the anti-tumor effect of gemcitabine on pancreatic cancer both in vitro and in vivo. Cancer Lett 293: 99-108, 2010.
13. Su YT, Chang HL, Shyue SK and Hsu SL: Emodin induces apoptosis in human lung adenocarcinoma cells through a reactive oxygen species-dependent mitochondrial signaling pathway. Biochem Pharmacol 70: 229-241, 2005.
14. Yi J, Yang J, He R Gao F, Sang H, Tang X and Ye RD: Emodin enhances arsenic trioxide-induced apoptosis via generation of reactive oxygen species and inhibition of survival signaling. Cancer Res 64: 108-116, 2004. (Pubitemid 38114088)
15. Gerlier D and Thomasset N: Use of MTT colorimetric assay to measure cell activation. J Immunol Methods 94: 57-63, 1986. (Pubitemid 17186343)
16. Guha S, Eibl G, Kisfalvi K, et al: Broad-spectrum G protein-coupled receptor antagonist, [D-Arg1,D-Trp5,7,9,Leu11]SP: a dual inhibitor of growth and angiogenesis in pancreatic cancer. Cancer Res 65: 2738-2745, 2005.
17. Jung CP, Motwani MV and Schwartz GK: Flavopiridol increases sensitization to gemcitabine in human gastrointestinal cancer cell lines and correlates with down-regulation of ribonucleotide reductase M2 subunit. Clin Cancer Res 7: 2527-2536, 2001. (Pubitemid 32751659)
18. Banerjee S, Zhang Y, Ali S, et al: Molecular evidence for increased antitumor activity of gemcitabine by genistein in vitro and in vivo using an orthotopic model of pancreatic cancer. Cancer Res 65: 9064-9072, 2005. (Pubitemid 41377399)
19. Kunnumakkara AB, Guha S, Krishnan S, Diagaradjane P, Gelovani J and Aggarwal BB: Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-kappaB-regulated gene products. Cancer Res 67: 3853-3861, 2007. (Pubitemid 46762173)
20. Cai J, Razzak A, Hering J, Saed A, Babcock TA, Helton S and Espat NJ: Feasibility evaluation of emodin (rhubarb extract) as an inhibitor of pancreatic cancer cell proliferation in vitro. JPEN J Parenter Enteral Nutr 32: 190-196, 2008. (Pubitemid 351464893)
21. Chang CJ, Ashendel CL, Geahlen RL, McLaughlin JL and Waters DJ: Oncogene signal transduction inhibitors from medicinal plants. In Vivo 10: 185-190, 1996. (Pubitemid 26001182)
22. Cha TL, Qiu L, Chen CT, Wen Y and Hung MC: Emodin down-regulates androgen receptor and inhibits prostate cancer cell growth. Cancer Res 65: 2287-2295, 2005. (Pubitemid 40490138)
23. Zhang L and Hung MC: Sensitization of HER-2/neu-overexpressing non-small cell lung cancer cells to chemotherapeutic drugs by tyrosine kinase inhibitor emodin. Oncogene 12: 571-576, 1996. (Pubitemid 26059652)
24. Zhang L, Lau YK, Xia W, Hortobagyi GN and Hung MC: Tyrosine kinase inhibitor emodin suppresses growth of HER-2/ neu-overexpressing breast cancer cells in athymic mice and sensitizes these cells to the inhibitory effect of paclitaxel. Clin Cancer Res 5: 343-353, 1999. (Pubitemid 29085188)
25. Lai GH, Zhang Z and Sirica AE: Celecoxib acts in a cyclooxygenase-2- independent manner and in synergy with emodin to suppress rat cholangiocarcinoma growth in vitro through a mechanism involving enhanced Akt inactivation and increased activation of caspases-9 and -3. Mol Cancer Ther 2: 265-271, 2003.
26. Guo Q, Chen Y, Zhang B, Kang M, Xie Q and Wu Y Potentiation of the effect of gemcitabine by emodin in pancreatic cancer is associated with survivin inhibition. Biochem Pharmacol 77: 1674-1683, 2009.
27. Hengartner MO: The biochemistry of apoptosis. Nature 407: 770-776, 2000.
28. Bargou RC, Daniel PT, Mapara MY, et al: Expression of the bcl-2 gene family in normal and malignant breast tissue: low bax-alpha expression in tumor cells correlates with resistance towards apoptosis. Int J Cancer 60: 854-859, 1995.
29. Friess H, Lu Z, Graber HU, et al: bax, but not bcl-2, influences the prognosis of human pancreatic cancer. Gut 43: 414-421, 1998. (Pubitemid 28414925)
30. Oltvai ZN, Milliman CL and Korsmeyer SJ: Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 74: 609-619, 1993. (Pubitemid 23259742)
31. Findley HW, Gu L, Yeager AM and Zhou M: Expression and regulation of Bcl-2, Bcl-x1, and Bax correlate with p53 status and sensitivity to apoptosis in childhood acute lymphoblastic leukemia. Blood 89: 2986-2993, 1997.
32. Miyashita T, Harigai M, Hanada M and Reed JC: Identification of a p53-dependent negative response element in the bcl-2 gene. Cancer Res 54: 3131-3135, 1994. (Pubitemid 24208916)
33. Arends JJ, Sleeboom HP, Leys MB, et al: A phase II study of raltitrexed and gemcitabine in patients with advanced pancreatic carcinoma. Br J Cancer 92: 445-448, 2005. (Pubitemid 40395524)
34. Berlin JD and Rothenberg ML: Chemotherapeutic advances in pancreatic cancer. Curr Oncol Rep 5: 219-226, 2003.
35. Diaz-Rubio E: New chemotherapeutic advances in pancreatic, colorectal, and gastric cancers. Oncologist 9: 282-294, 2004.